Phaseline

Targets › IL15RA

IL15RA (Interleukin-15 receptor subunit alpha): drug programs, companies and trials

3 programs from 3 companies in 27 trials: 15 Phase 2, 11 Phase 1, 1 Phase 3; Oncology, Infectious disease; next expected readout Dec 2026.

High-affinity receptor for interleukin-15. Can signal both in cis and trans where IL15R from one subset of cells presents IL15 to neighboring IL2RG-expressing cells (By similarity). (UniProt, Q13261)

Open in Phaseline: the race on IL15RA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ImmunityBioNogapendekin Alfa Inbakicept (N803)
Interleukin-15 receptor agonist
IL2RG, IL2RB, IL15RAPhase 3NSCLC Stage IV; Long COVID; Platinum-resistant Ovarian Cancer; Relapsed B-Cell Non Hodgkin Lymphoma …Mar 2027
Suzhou Forlong BiotechnologyFL115
IL-15 agonist (IL-15[N72D]/IL-15Rα-sFc fusion protein)
IL15, IL15RAPhase 1Locally Advanced/Metastatic Solid Tumors; Advanced Solid Tumors; Non-muscle Invasive Bladder Cancer (NMIBC)Dec 2026
National Cancer Institute (NCI)Recombinant Human Interleukin-15 (rhIL-15)
Interleukin-15 receptor agonist
IL2RG, IL2RB, IL15RAPhase 1NeuroblastomaJun 2028

Conditions

Long COVID (2) NSCLC Stage IV (1) Platinum-resistant Ovarian Cancer (1) Relapsed B-Cell Non Hodgkin Lymphoma (1) Pancreatic Cancer (1) Bladder Cancer (1) Non-Small Cell Lung Cancer (1) Glioblastoma (1) Non Hodgkin's Lymphoma Refractory/Relapsed (1) Metastatic Solid Tumor (1) Non-muscle Invasive Bladder Cancer (1) HIV/AIDS (1)

Modalities

mixed (2), small molecule (1)

Companies

ImmunityBio (1) National Cancer Institute (NCI) (1) Suzhou Forlong Biotechnology (1)

Related targets

IL2RG (2) IL2RB (2) IL15 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.